{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/45767"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/45767","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"Conditional prognostication of non-muscle invasive bladder cancer: a SEER-Medicare analysis","abstract":"BACKGROUND: The risk of recurrence and progression is high among patients with non-muscle invasive bladder cancer (NMIBC). The challenge in disease management underlines the importance of accurate prognostic assessment. The risk profile of patients is expected to change at different follow-up times. Thereby, recurrence and progression rates during follow-up may differ from those estimated at diagnosis. Conditional survival, a prognostic measure that accounts for the time survived since diagnosis, provides a more accurate estimate than conventional survival estimated at time zero. OBJECTIVE: To assess the 6-, 12-, 24-, 36-, and 60-month conditional recurrence-free survival (RFS) and progression-free survival (PFS) after index transurethral resection of bladder tumor (TURBT). METHODS: The Surveillance, Epidemiology and End Results (SEER)-Medicare linked database was queried to identify patients aged ≥66-89 years diagnosed with Ta/Tis/T1 cN0 cM0 urothelial carcinoma of bladder (UCB) from 2000 to 2017. Conditional RFS and PFS estimates were estimated using the Kaplan-Meier method at pre-specified landmark times for the overall cohort and stratified by T stage and tumor grade. Univariable and multivariable Cox proportional hazards models were used to evaluate the associations of baseline characteristics with RFS and PFS at pre-specified landmark times. RESULTS: The 60-month conditional RFS and PFS at baseline were 0.39 and 0.93 respectively. Given a 6, 12, 24, 36, 48, 60 months event-free survivorship, the 60-month RFS were 0.52, 0.63, 0.73, 0.78, 0.82, and 0.85 respectively; PFS were 0.94, 0.95, 0.96, 0.97, 0.97, and 0.97 respectively. Conditional RFS and PFS rapidly improved within the first 24 months and then plateaued. When stratified by T stage, patients with T1 tumors had significantly shorter RFS and PFS (p<0.01); however, the most notable survival gain with additional years survived was observed in this subgroup. On multivariable analyses, T stage at diagnosis was less predictive of RFS and PFS with longer landmark times, while tumor grade and female gender remained significant independent predictors of RFS and PFS. CONCLUSION: The conditional survival analyses demonstrated improved survivorship with increased recurrence- and progression-free intervals. The risk of experiencing an event attenuated overtime with converging rates of survivorship across grade-stage subgroups. These data offer dynamic prognostication in directing more personalized care for patients with NMIBC.","abstract_html":"BACKGROUND: The risk of recurrence and progression is high among patients with non-muscle invasive bladder cancer (NMIBC). The challenge in disease management underlines the importance of accurate prognostic assessment. The risk profile of patients is expected to change at different follow-up times. Thereby, recurrence and progression rates during follow-up may differ from those estimated at diagnosis. Conditional survival, a prognostic measure that accounts for the time survived since diagnosis, provides a more accurate estimate than conventional survival estimated at time zero. OBJECTIVE: To assess the 6-, 12-, 24-, 36-, and 60-month conditional recurrence-free survival (RFS) and progression-free survival (PFS) after index transurethral resection of bladder tumor (TURBT). METHODS: The Surveillance, Epidemiology and End Results (SEER)-Medicare linked database was queried to identify patients aged ≥66-89 years diagnosed with Ta/Tis/T1 cN0 cM0 urothelial carcinoma of bladder (UCB) from 2000 to 2017. Conditional RFS and PFS estimates were estimated using the Kaplan-Meier method at pre-specified landmark times for the overall cohort and stratified by T stage and tumor grade. Univariable and multivariable Cox proportional hazards models were used to evaluate the associations of baseline characteristics with RFS and PFS at pre-specified landmark times. RESULTS: The 60-month conditional RFS and PFS at baseline were 0.39 and 0.93 respectively. Given a 6, 12, 24, 36, 48, 60 months event-free survivorship, the 60-month RFS were 0.52, 0.63, 0.73, 0.78, 0.82, and 0.85 respectively; PFS were 0.94, 0.95, 0.96, 0.97, 0.97, and 0.97 respectively. Conditional RFS and PFS rapidly improved within the first 24 months and then plateaued. When stratified by T stage, patients with T1 tumors had significantly shorter RFS and PFS (p&lt;0.01); however, the most notable survival gain with additional years survived was observed in this subgroup. On multivariable analyses, T stage at diagnosis was less predictive of RFS and PFS with longer landmark times, while tumor grade and female gender remained significant independent predictors of RFS and PFS. CONCLUSION: The conditional survival analyses demonstrated improved survivorship with increased recurrence- and progression-free intervals. The risk of experiencing an event attenuated overtime with converging rates of survivorship across grade-stage subgroups. These data offer dynamic prognostication in directing more personalized care for patients with NMIBC.","abstract_has_math":false,"creators":["Chang, Chia-Chen"],"institution":"Boston University","degree_name":"Master of Science","degree_level":"masters","degree_discipline":"Medical Sciences","degree_department":null,"school":null,"contributors":[],"advisors":["Symes, Karen","Gershman, Boris"],"committee_chairs":[],"committee_members":[],"year":2022,"date_issued":"2022","date_published":"2022","updated_at":"2026-11-18T20:20:53Z","subjects":["Oncology","Bladder cancer","Conditional progression-free survival","Conditional recurrence-free survival","Conditional survival","Non-muscle invasive bladder cancer","Urology"],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2144/45767","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/45767","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F45767","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Symes, Karen","Gershman, Boris"]},{"key":"dc:creator","label":"Author","values":["Chang, Chia-Chen"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2023-03-21T13:24:38Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2023-03-21T13:24:38Z"]},{"key":"dc:date.issued","label":"Date","values":["2022"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2023-03-20T16:04:50Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Medical Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["masters"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Oncology","Bladder cancer","Conditional progression-free survival","Conditional recurrence-free survival","Conditional survival","Non-muscle invasive bladder cancer","Urology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/45767"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["BACKGROUND: The risk of recurrence and progression is high among patients with non-muscle invasive bladder cancer (NMIBC). The challenge in disease management underlines the importance of accurate prognostic assessment. The risk profile of patients is expected to change at different follow-up times. Thereby, recurrence and progression rates during follow-up may differ from those estimated at diagnosis. Conditional survival, a prognostic measure that accounts for the time survived since diagnosis, provides a more accurate estimate than conventional survival estimated at time zero. OBJECTIVE: To assess the 6-, 12-, 24-, 36-, and 60-month conditional recurrence-free survival (RFS) and progression-free survival (PFS) after index transurethral resection of bladder tumor (TURBT). METHODS: The Surveillance, Epidemiology and End Results (SEER)-Medicare linked database was queried to identify patients aged ≥66-89 years diagnosed with Ta/Tis/T1 cN0 cM0 urothelial carcinoma of bladder (UCB) from 2000 to 2017. Conditional RFS and PFS estimates were estimated using the Kaplan-Meier method at pre-specified landmark times for the overall cohort and stratified by T stage and tumor grade. Univariable and multivariable Cox proportional hazards models were used to evaluate the associations of baseline characteristics with RFS and PFS at pre-specified landmark times. RESULTS: The 60-month conditional RFS and PFS at baseline were 0.39 and 0.93 respectively. Given a 6, 12, 24, 36, 48, 60 months event-free survivorship, the 60-month RFS were 0.52, 0.63, 0.73, 0.78, 0.82, and 0.85 respectively; PFS were 0.94, 0.95, 0.96, 0.97, 0.97, and 0.97 respectively. Conditional RFS and PFS rapidly improved within the first 24 months and then plateaued. When stratified by T stage, patients with T1 tumors had significantly shorter RFS and PFS (p<0.01); however, the most notable survival gain with additional years survived was observed in this subgroup. On multivariable analyses, T stage at diagnosis was less predictive of RFS and PFS with longer landmark times, while tumor grade and female gender remained significant independent predictors of RFS and PFS. CONCLUSION: The conditional survival analyses demonstrated improved survivorship with increased recurrence- and progression-free intervals. The risk of experiencing an event attenuated overtime with converging rates of survivorship across grade-stage subgroups. These data offer dynamic prognostication in directing more personalized care for patients with NMIBC."]},{"key":"dc:title","label":"Title","values":["Conditional prognostication of non-muscle invasive bladder cancer: a SEER-Medicare analysis"]}]}],"canonical_facts":{"dc:contributor.advisor":["Symes, Karen","Gershman, Boris"],"dc:creator":["Chang, Chia-Chen"],"dc:date.accessioned":["2023-03-21T13:24:38Z"],"dc:date.available":["2023-03-21T13:24:38Z"],"dc:date.issued":["2022"],"dc:date.updated":["2023-03-20T16:04:50Z"],"dc:description.abstract":["BACKGROUND: The risk of recurrence and progression is high among patients with non-muscle invasive bladder cancer (NMIBC). The challenge in disease management underlines the importance of accurate prognostic assessment. The risk profile of patients is expected to change at different follow-up times. Thereby, recurrence and progression rates during follow-up may differ from those estimated at diagnosis. Conditional survival, a prognostic measure that accounts for the time survived since diagnosis, provides a more accurate estimate than conventional survival estimated at time zero. OBJECTIVE: To assess the 6-, 12-, 24-, 36-, and 60-month conditional recurrence-free survival (RFS) and progression-free survival (PFS) after index transurethral resection of bladder tumor (TURBT). METHODS: The Surveillance, Epidemiology and End Results (SEER)-Medicare linked database was queried to identify patients aged ≥66-89 years diagnosed with Ta/Tis/T1 cN0 cM0 urothelial carcinoma of bladder (UCB) from 2000 to 2017. Conditional RFS and PFS estimates were estimated using the Kaplan-Meier method at pre-specified landmark times for the overall cohort and stratified by T stage and tumor grade. Univariable and multivariable Cox proportional hazards models were used to evaluate the associations of baseline characteristics with RFS and PFS at pre-specified landmark times. RESULTS: The 60-month conditional RFS and PFS at baseline were 0.39 and 0.93 respectively. Given a 6, 12, 24, 36, 48, 60 months event-free survivorship, the 60-month RFS were 0.52, 0.63, 0.73, 0.78, 0.82, and 0.85 respectively; PFS were 0.94, 0.95, 0.96, 0.97, 0.97, and 0.97 respectively. Conditional RFS and PFS rapidly improved within the first 24 months and then plateaued. When stratified by T stage, patients with T1 tumors had significantly shorter RFS and PFS (p<0.01); however, the most notable survival gain with additional years survived was observed in this subgroup. On multivariable analyses, T stage at diagnosis was less predictive of RFS and PFS with longer landmark times, while tumor grade and female gender remained significant independent predictors of RFS and PFS. CONCLUSION: The conditional survival analyses demonstrated improved survivorship with increased recurrence- and progression-free intervals. The risk of experiencing an event attenuated overtime with converging rates of survivorship across grade-stage subgroups. These data offer dynamic prognostication in directing more personalized care for patients with NMIBC."],"dc:identifier.uri":["https://hdl.handle.net/2144/45767"],"dc:language.iso":["en_US"],"dc:subject":["Oncology","Bladder cancer","Conditional progression-free survival","Conditional recurrence-free survival","Conditional survival","Non-muscle invasive bladder cancer","Urology"],"dc:title":["Conditional prognostication of non-muscle invasive bladder cancer: a SEER-Medicare analysis"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Medical Sciences"],"thesis:degree_level":["masters"],"thesis:degree_name":["Master of Science"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-18T20:20:53Z"}